Valuation: Simulations Plus

Market Cap 372M 339M 314M 284M 533M 34.76B 557M 3.79B 1.5B 18.78B 1.4B 1.37B 59.49B P/E 2024
74x
P/E 2025 -4.4x
Enterprise Value 340M 310M 287M 260M 487M 31.79B 510M 3.47B 1.38B 17.18B 1.28B 1.25B 54.42B EV / Sales 2024
10.1x
EV / Sales 2025 3.2x
Free-Float
99.59%
Yield 2024
0.66%
Yield 2025 -
3 months+0.71%
6 months+31.21%
Current year+1.48%
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.81
Extreme 8.81
90.92
Manager TitleAgeSince
Chief Executive Officer 67 25/06/2018
Director of Finance/CFO 63 30/11/2020
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Issuer sale

Chairman

-23,547 0.1169%
06/10/26 Issuer sale

Chief Financial Officer

-109,600 0.5440%
06/10/26 Issuer sale

Founder

-3,207,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+13.36%-52.66% 374M
-0.58%-1.53%+20.04%+47.67% 255B
-0.45%-1.98%+2.32%+9.52% 160B
-3.26%-7.42%-27.88%+33.40% 141B
-1.49%-2.74%-55.68%-20.89% 62.31B
-1.28%-1.81%+20.76%+55.28% 59.73B
-1.36%-1.71%+4.63%-13.60% 53.49B
-1.12%+1.35%+21.43%+54.96% 49.43B
-2.06%-1.24%+21.32%+74.31% 44.87B
-5.15%-13.06%-3.69%+48.93% 42.57B
Average -1.22%-2.96%+1.66%+23.69% 87B
Weighted average by Cap. -0.84%-3.60%+1.64%+31.97%

Financials

2024 2025
Net sales 70.01M 63.79M 59.05M 53.41M 100M 6.54B 105M 714M 283M 3.53B 263M 257M 11.19B 79.18M 72.14M 66.78M 60.4M 113M 7.39B 119M 807M 320M 4B 297M 291M 12.66B
Net income 9.95M 9.07M 8.4M 7.59M 14.25M 930M 14.91M 101M 40.25M 502M 37.34M 36.56M 1.59B -64.72M -58.96M -54.58M -49.37M -92.62M -6.04B -96.94M -660M -262M -3.27B -243M -238M -10.35B
Net Debt -19.25M -17.54M -16.23M -14.68M -27.55M -1.8B -28.83M -196M -77.84M -971M -72.22M -70.7M -3.08B -31.74M -28.92M -26.77M -24.21M -45.42M -2.96B -47.54M -324M -128M -1.6B -119M -117M -5.07B
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Simulations Plus